Protocol Ledger

NCT04596150 · Phase II · COMPLETED

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Interventional Phase II clinical trial protocol NCT04596150 sponsored by CytomX Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-29 Enrollment: 125 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04596150
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)125 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04596150
Protocol FieldVerified Registry Value
NCT IdentifierNCT04596150
Consolidated Lead SponsorCytomX Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment125 participants (ACTUAL)
Registered Start Date2020-12-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI